EMA Lapsed: Fablyn (Lasofoxifene tartrate) — Dr. Friedrich Eberth Arzneimittel GmbH

View source ↗

Summary

EMA indicates the marketing authorization for Fablyn (lasofoxifene tartrate) has lapsed, primarily in the osteoporosis/postmenopausal setting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Fablyn (lasofoxifene tartrate)

Snippet

Status: Lapsed. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Dr. Friedrich Eberth Arzneimittel GmbH. Decision date: 27/02/2012